Rubinder Dab, MD
Cardiovascular Disease · Richmond, INNPI 1467430728
Payments from drug & device makers
Across 298 payments — averaging $1824.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$505K
- Boehringer Ingelheim International GmbH$17K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$15K
- Boehringer Ingelheim Pharma GmbH & Co.kg$4K
- Abbott$395
- AstraZeneca$323
- plus $3K from 32 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 53 | $504,777 |
| Boehringer Ingelheim International GmbH | 64 | $17,317 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $14,535 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $3,558 |
| Abbott | 19 | $395 |
| AstraZeneca | 15 | $323 |
| Pfizer | 19 | $311 |
| E.r. Squibb & Sons, L.L.C. | 17 | $267 |
| Boston Scientific | 5 | $238 |
| Merck | 11 | $192 |
| Amgen | 9 | $175 |
| Heartflow, Inc. | 7 | $163 |
| Johnson & Johnson | 8 | $144 |
| Novo Nordisk | 6 | $135 |
| Sanofi-aventis U.S. LLC | 9 | $133 |
| Alnylam Pharmaceuticals Inc. | 6 | $127 |
| Scpharmaceuticals Inc. | 5 | $99 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $87 |
| Daiichi Sankyo Inc. | 4 | $75 |
| Actelion Pharmaceuticals US, Inc. | 4 | $65 |
| Abiomed | 2 | $57 |
| Boehringer Ingelheim | 3 | $44 |
| Medtronic | 1 | $34 |
| GSK | 2 | $32 |
| Lexicon Pharmaceuticals, Inc. | 2 | $32 |
| Bayer | 2 | $32 |
| Tactile Systems Technology Inc | 2 | $30 |
| Amarin Pharma, Inc. | 1 | $25 |
| Altathera Pharmaceuticals LLC | 2 | $25 |
| Edwards Lifesciences | 1 | $24 |
| Cvrx, Inc. | 2 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Inari Medical, Inc. | 1 | $13 |
| Gilead | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$543,559 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Richmond
- John McGintyRichmond$3.7M
- Steven SteinhublLafayette$2.4M
- Ravi BhagwatMunster$2.2M
- Mohan KesaniMunster$1.2M
- Vijay MehtaElkhart$925K
- William CollisFort Wayne$842K
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
- Wail AsfourMunster$736K
- Vijay RaoIndianapolis$706K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.